Stockscreener 앱 받기
0.0982
69.12%
-0.2198
Hepion Pharmaceuticals Inc 주식(HEPA)의 최신 뉴스
Hepion Pharmaceuticals Delays Form 10-Q Filing - TipRanks
Hepion Pharmaceuticals, Inc.(OTCPK: HEPA) dropped from S&P TMI Index - marketscreener.com
Hepion Pharmaceuticals Announces Receipt of Delisting Notificati - GuruFocus
Hepion Pharmaceuticals (NASDAQ:HEPA) Trading Down 18.8% – Should You Sell? - Defense World
Hepion Pharma Stock Draws Bullish Retail Bets Despite Nasdaq Delisting Notice: 'Could Get Interesting' - NewsBreak: Local News & Alerts
Hepion Pharma Stock Draws Bullish Retail Bets Despite Nasdaq Delisting Notice: ’Could Get Interesting’ By Stocktwits - Investing.com India
Hepion Pharmaceuticals (HEPA) Faces Nasdaq Delisting, Moves to O - GuruFocus
Hepion Pharmaceuticals (HEPA) to be Delisted from Nasdaq | HEPA Stock News - GuruFocus
Hepion Pharmaceuticals Faces Nasdaq Delisting Notice - TipRanks
Hepion Pharmaceuticals to be delisted from Nasdaq - Investing.com
Hepion Pharmaceuticals to be delisted from Nasdaq By Investing.com - Investing.com India
Hepion Pharmaceuticals Initiates Transition to OTC Markets Following Nasdaq Delisting Notice - Nasdaq
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq - GlobeNewswire
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
HEPA Collaborates with New Day Diagnostics on Lucrative Diagnostic Tests | HEPA Stock News - GuruFocus
Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC | HEPA Stock News - GuruFocus
Hepion Pharmaceuticals inks deal to license diagnostic tests - Investing.com
Hepion Pharmaceuticals enters binding LOI with New Day Diagnostics - TipRanks
Hepion Pharmaceuticals inks deal to license diagnostic tests By Investing.com - Investing.com Nigeria
Hepion Pharmaceuticals Executes Binding Letter of Intent - GlobeNewswire
Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC - Stock Titan
Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing - marketscreener.com
Stocks of Hepion Pharmaceuticals Inc (HEPA) are poised to climb above their peers - Sete News
Financial Analysis: Hepion Pharmaceuticals (NASDAQ:HEPA) versus Salarius Pharmaceuticals (NASDAQ:SLRX) - Defense World
HEPA’s 52-Week Rollercoaster: From $0.25 to $79.50 – What’s Next for Investors? - investchronicle.com
Examining HEPA’s book value per share for the latest quarter - uspostnews.com
Press Release Distribution & PR Platform - ACCESS Newswire
Hepion Pharmaceuticals, Inc. Announces Closing of Public Offering - ACCESS Newswire
Holdings of Hepion Pharmaceuticals Inc (HEPA) are aligned with the stars - Sete News
Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Price Down 2% – What’s Next? - Defense World
Hepion Pharmaceuticals (HEPA) Ends Merger with Pharma Two B - GuruFocus
Hepion Pharmaceuticals (HEPA) Announces $9M Public Offering Laun - GuruFocus
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference - ACCESS Newswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Pharma Two B Presents Positive P2B001 Data for Parkinson's Disea - GuruFocus
Hepion Pharmaceuticals (HEPA) to Implement 1-for-50 Reverse Stoc - GuruFocus
Hepion Pharmaceuticals, Inc. SEC 10-K Report - TradingView
HEPA stock touches 52-week low at $0.39 amid sharp annual decline - Investing.com Canada
Is Hepion Pharmaceuticals Inc’s -99.59% Fall This Year Is A Better Investing Opportunity? - Marketing Sentinel
Before You Invest, Make Sure You Check This Hepion Pharmaceuticals Inc (NASDAQ: HEPA) Analysis - Stocksregister
Hepion Pharmaceuticals Delays Annual Report Filing - TipRanks
Is Hepion Pharmaceuticals Inc (HEPA) worth investing in despite its undervalued state? - uspostnews.com
Hepion Pharmaceuticals announces 1-for-50 reverse stock split - MSN
Hepion Pharmaceuticals Inc (NASDAQ: HEPA) Fall -98.12% In Six Months, Here’s What We Should Expect Now - Marketing Sentinel
HEPA stock plunges to 52-week low, touches $0.67 By Investing.com - Investing.com UK
Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Price Down 7.2% – Here’s Why - Defense World
Hepion Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com South Africa
Hepion Pharmaceuticals faces potential Nasdaq delisting - Investing.com
Hepion Pharmaceuticals enacts reverse stock split By Investing.com - Investing.com India
Hepion Pharmaceuticals enacts reverse stock split - Investing.com
Hepion Pharmaceuticals Announces 1-for-50 Reverse Stock Split Effective March 17, 2025 - Nasdaq
0.77%
자본화:
|
볼륨(24시간):